Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.18
-5.93 (-2.82%)
AAPL  266.56
+1.98 (0.75%)
AMD  194.81
-5.34 (-2.67%)
BAC  51.34
-1.72 (-3.23%)
GOOG  310.59
-4.31 (-1.37%)
META  637.11
-18.55 (-2.83%)
MSFT  384.20
-13.03 (-3.28%)
NVDA  190.44
+0.62 (0.32%)
ORCL  139.80
-8.28 (-5.59%)
TSLA  395.44
-16.38 (-3.98%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.